Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel S Merseburger

Showing results (61-70 of 323) with videos related to

Pageof 33
Sort By:
The Lancet. Oncology|October 2, 2025
CONTACT-02: limited clinical benefit and a suboptimal control group - Authors' replyNeeraj Agarwal, Axel S Merseburger, Svetlana Andrianova, et al.
Translational Andrology and Urology|November 19, 2020
Why is the principle of "as much radicality as needed, as much organ preservation as possible" only insufficiently implemented in daily practice in the surgical treatment of penile cancer patients?Matthias May, Michael Rink, Axel S Merseburger, et al.
Proteomics. Clinical Applications|October 6, 2017
Clinical Proteomics for Precision Medicine: The Bladder Cancer CaseAgnieszka Latosinska, Maria Frantzi, Antonia Vlahou, et al.
Advances in Therapy|August 6, 2018
A New Automatically Fixating Stone Basket (2.5 F) Prototype with a Nitinol Spring for Accurate Ureteroscopic Stone Size MeasurementJens Cordes, Felix Nguyen, Wolfhard Pinkowski, et al.
Frontiers in Oncology|June 14, 2021
Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World SettingAxel S Merseburger, Götz Geiges, Jörg Klier, et al.
Journal of Contemporary Brachytherapy|July 10, 2023
Salvage high-dose-rate interventional radiotherapy (brachytherapy) for locally relapsed prostate cancer after radical prostatectomy and subsequent external irradiationTamer Soror, Corrina Melchert, Dirk Rades, et al.
The Oncologist|May 15, 2013
Perspectives on treatment of metastatic castration-resistant prostate cancerAxel S Merseburger, Joaquim Bellmunt, Cheryl Jenkins, et al.
The Oncologist|February 19, 2014
In replyAxel S Merseburger, Joaquim Bellmunt, Cheryl Jenkins, et al.
Aktuelle Urologie|August 8, 2019
[Status quo 5 years after the introduction of the new ISUP 2014/WHO 2016 prostate cancer grade groups]Marie Christine Hupe, Anne Offermann, Verena Sailer, et al.
Expert Opinion on Pharmacotherapy|November 10, 2016
Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancerM Raschid Hoda, Mario W Kramer, Axel S Merseburger, et al.
Pageof 33

Showing results (61-70 of 323) with videos related to

Sort By:
Pageof 33
The Lancet. Oncology|October 2, 2025
CONTACT-02: limited clinical benefit and a suboptimal control group - Authors' replyNeeraj Agarwal, Axel S Merseburger, Svetlana Andrianova, et al.
Translational Andrology and Urology|November 19, 2020
Why is the principle of "as much radicality as needed, as much organ preservation as possible" only insufficiently implemented in daily practice in the surgical treatment of penile cancer patients?Matthias May, Michael Rink, Axel S Merseburger, et al.
Proteomics. Clinical Applications|October 6, 2017
Clinical Proteomics for Precision Medicine: The Bladder Cancer CaseAgnieszka Latosinska, Maria Frantzi, Antonia Vlahou, et al.
Advances in Therapy|August 6, 2018
A New Automatically Fixating Stone Basket (2.5 F) Prototype with a Nitinol Spring for Accurate Ureteroscopic Stone Size MeasurementJens Cordes, Felix Nguyen, Wolfhard Pinkowski, et al.
Frontiers in Oncology|June 14, 2021
Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World SettingAxel S Merseburger, Götz Geiges, Jörg Klier, et al.
Journal of Contemporary Brachytherapy|July 10, 2023
Salvage high-dose-rate interventional radiotherapy (brachytherapy) for locally relapsed prostate cancer after radical prostatectomy and subsequent external irradiationTamer Soror, Corrina Melchert, Dirk Rades, et al.
The Oncologist|May 15, 2013
Perspectives on treatment of metastatic castration-resistant prostate cancerAxel S Merseburger, Joaquim Bellmunt, Cheryl Jenkins, et al.
The Oncologist|February 19, 2014
In replyAxel S Merseburger, Joaquim Bellmunt, Cheryl Jenkins, et al.
Aktuelle Urologie|August 8, 2019
[Status quo 5 years after the introduction of the new ISUP 2014/WHO 2016 prostate cancer grade groups]Marie Christine Hupe, Anne Offermann, Verena Sailer, et al.
Expert Opinion on Pharmacotherapy|November 10, 2016
Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancerM Raschid Hoda, Mario W Kramer, Axel S Merseburger, et al.
Pageof 33